Home > Insider Trading > Filing (0001209191-21-026747)

Filing Details

Accession Number:: 0001209191-21-026747
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-04-14 20:19:04
Reporting Period:: 2021-04-12

Accepted Time:: 2021-04-14 20:19:04
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1733294	Generation Bio Co.	GBIO	Pharmaceutical Preparations (2834)	814301281

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1742765	Atlas Venture Associates X, Llc	300 Technology Square, 8Th Floor Cambridge MA 02139		No	No	Yes	No
1742766	Atlas Venture Associates X, L.p.	300 Technology Square, 8Th Floor Cambridge MA 02139		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2021-04-12	63,353	$26.07	77,329	No	4	S	Direct
Common Stock	Disposition	2021-04-12	10,771	$26.61	66,558	No	4	S	Direct
Common Stock	Disposition	2021-04-13	35,791	$25.09	30,767	No	4	S	Direct
Common Stock	Disposition	2021-04-13	7,354	$25.53	23,413	No	4	S	Direct
Common Stock	Disposition	2021-04-14	10,539	$26.40	12,874	No	4	S	Direct
Common Stock	Disposition	2021-04-14	12,874	$26.78	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	9,111,939	Indirect	See footnote

Footnotes

Shares were sold pursuant to a Rule 10b5-1 trading plan dated January 14, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.405 to $26.40 inclusive. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5), (6), (7) and (8).
The shares are held directly by Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. AVA X LLC disclaims Section 16 beneficial ownership of the securities held by AVA X LP except to the extent of its pecuniary interest therein, if any.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.41 to $27.20 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.37 to $25.36 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.37 to $26.04 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.58 to $26.57 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.58 to $27.14 inclusive.
These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is AVA X LP and the general partner of AVA X LP is AVA X LLC. Each of AVA X LP and AVA LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend of its respective pecuniary interest therein, if any.